Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 413-422

  Perno, Carlo Federico ^a   Newcomb, Fonda M ^a   Davis, David A ^a   Aquaro, Stefano ^a   Humphrey, Rachel W ^b   Caliò, Raffaele ^a   Yarchoan, Robert ^a  

^a MSC 1906 ^*

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MACROPHAGE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0031848314     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515642     Document Type: Article

References (23)

1. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-61.
2. Meek TD, Lambert DM, Dreyer GB, et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 1990;343:90-2.
3. 2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother 1992;36:926-33.
4. Kempf D, Marsh K, Denissen J. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-8.
5. Gathe J Jr, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S. A randomized phase II study of VIRACEPT, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone [abstract Mo.B.413]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
6. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53.
7. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996;10(suppl A): S151-7.
8. St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996;29:53-6.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-54.
10. + T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
11. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-9.
12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
13. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
14. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent;HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
15. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
16. McQuade TJ, Tomasselli AG, Liu L, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 1990;247:454-6.
17. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321:726-38.
18. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990;249:1533-44.
19. Massari F, Conant M, Mellors J, et al. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV), and didanosine (ddI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract 200]. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.
20. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
21. Condra JH, Holder DJ, Schleif WA, et al. Bi-directional inhibition of HIV1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors [abstract Th.B.932]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
22. Lambert DM, Petteway SR Jr, McDanal CE, et al. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992;36:982-8.
23. Kort JJ, Bilello JA, Bauer G, Drusano GL. Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1993;37:115-9.